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Abstract: Background: The incidence of acute coronary syndrome is reported to be higher 
for males than females, yet clinical outcomes following acute myocardial infarction are 
worse among females. Information about acute coronary syndrome outcomes is obtained 
from randomised and cohort data. However, randomised controlled trials which are designed 
to evaluate the efficacy of clinical interventions often have limited external validity, and 
observational studies which draw inferences from the effect of an exposure whilst being 
more generalizable are limited by confounding. Methods: We undertook a structured litera-
ture review of research manuscripts published between 2000 and 2015 to examine whether 
reported sex-dependent outcomes following acute coronary syndrome differed between 
randomised control trials and observational registries. Results: Of 56 manuscripts, we found 
consistency between the two types of study designs  each type of study describing worse 
clinical outcomes for females with acute coronary syndrome. We also found a reduction in 
the use of guideline recommended therapy in females. Conclusion: Further research is needed to understand at a 
mechanistic and health services level why such a discrepancy in clinical outcomes exists. 
Keywords: Acute coronary syndrome, sex outcomes, trials, registries. 
INTRODUCTION 
 It is well recognised that the incidence of ischaemic heart dis-
ease is higher for males than females, and that males have a higher 
mortality rates from ischaemic heart disease [1]. For acute myocar-
dial infarction (AMI), however, a number of studies suggest that 
mortality rates are higher among females than males [2,3]. Informa-
tion about acute coronary syndrome (ACS) outcomes is obtained 
from randomised and cohort data. Randomised controlled trials 
(RCT) are designed to evaluate the efficacy of clinical interven-
tions, but often have limited external validity. Observational studies 
draw inferences from the effect of an exposure and, whilst being 
more generalizable, are limited by confounding [4,5]. Therefore, we 
aimed to examine whether reported sex-dependent outcomes fol-
lowing ACS differed between RCTs and observational registries. 
We focus initially on the results of RCTs, then observational regis-
tries and finally compare and contrast the results from the two types 
of study design.  
METHODS 
 We followed the PRISMA guidelines to conduct a structured 
literature review [6]. A Medline search strategy was developed and 
adapted for CINAHL, EMBASE, Web of Science and AMED. All 
databases were searched from 1
st
 January, 2000 to the 18
th
 Septem-
ber, 2015. The search was restricted to English language publica-
tions. A full search strategy can be found in Appendix 1. 
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Eligibility Criteria 
 All abstracts were reviewed and potentially eligible studies 
selected (OB). Eligible studies were those, which assessed patients 
with ACS, included females in their cohort, were either based on 
registry or randomised data and provided outcomes with respect to 
sex. Meta-analyses were reviewed if they met the above criteria. 
Manuscripts were restricted to those where the full text was avail-
able in English; posters and conference abstracts were excluded. 
Eligible manuscripts were reviewed in full and their references used 
to identify additional manuscripts. Whenever possible, supplemen-
tary data specifically concerning subgroup analyses were sought 
and reviewed where available. When reviewing eligible manu-
scripts for further manuscripts, the time restrictions were not ap-
plied. Fig. (1) shows the flow of selection of manuscripts from the 
search engines.  
RESULTS 
 In total 56 manuscripts fulfilled the inclusion criteria (Fig. 1). 
There were 29 manuscripts about RCTs and 27 observational regis-
tries. There were seven RCTs and seven observational registry 
manuscripts that focussed on reperfusion strategies. Twenty one 
manuscripts considered the utilisation of medications (fourteen 
RCTs and one observational registry). Eleven manuscripts consid-
ered an invasive strategy as the primary focus of the article, of 
which eight manuscripts were about RCTs (concerning three differ-
ent trials) compared with three observational registry studies. 
 Twelve registry manuscripts primarily focussed on outcomes 
whilst four considered the incidence of acute myocardial infarction 
(AMI) or its risk factors. 
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 The total number of patients across all included studies was 
2,538,327 of which 308,781 patients were in RCT and 2,229,546 in 
observational registries. 
 The proportion of females in the selected manuscripts was, on 
average, 31.5%, being 28%, range 18% to 38% for RCTs and 35%, 
range 24% to 52% for observational registries. 
Reperfusion Therapy for AMI - RCTs 
 The long-term outcomes for 30-day survivors of AMI who were 
in the Global Utilisation of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO 1) trial of four 
different thrombolytic strategies (Streptokinase and intravenous 
heparin, streptokinase and subcutaneous heparin, tissue plasmino-
gen activator (t-PA) and intravenous heparin and a combination of 
streptokinase, t-PA and intravenous heparin were worse among 
females. The Kaplan Meier estimated mortality rates were 36.2% 
for females vs. 29.5% for males (P<0.0001) [7]. A higher propor-
tion of females had cardiogenic shock 33.9% vs. 25.6%. Multivari-
able regression estimated a hazard ratio of 1.21 - suggesting that, on 
average, the risk of death was 21% higher for females. The Interna-
tional Studies of Infarct Survival (ISIS2) trial investigated the effi-
cacy of aspirin and streptokinase both individually and combined 
on 35-day mortality for AMI. The proportion of females was 23%. 
Survival was greatest for the combination of aspirin and strepto-
kinase and, although evident across both sexes, males gained more 
from the intervention than females. Moreover, females fared worse 
across all groups  mortality rates being 14.6% among females 
compared with 9.4% among males [8].  
 The ISIS 1 trial of intravenous atenolol among patients hospi-
talised with AMI reported higher rates of mortality at 7 days for 
females in both the intervention 5.2% vs. 3.5% and control groups 
7.5% vs. 3.7% [9]. The Should We Emergently Revascularise Oc-
cluded Coronaries for Cardiogenic Shock (SHOCK) trial comparing 
emergency revascularisation (angioplasty or bypass surgery) vs. 
medical stabilisation (which could include intra-aortic balloon 
pump and thrombolysis) at up to 11 years follow-up among patients 
with AMI complicated by cardiogenic shock comprised 32% fe-
males. The study demonstrated improved survival with early revas-
cularisation, but did not demonstrate any interaction between the 
treatment assigned and sex, or that sex was an independent risk 
factor [10]. The Gruppo Italiano per lo Studio della Sopravvivenza 
nell'Infarto Miocardico (GISSI) trial investigated the use of strepto-
kinase in AMI patients. It demonstrated improved outcomes among 
those who received streptokinase across both sexes. Even so they 
demonstrated higher mortality rates for females compared with 
males in both those who received streptokinase and in the control 
group (28.3% vs. 14.5% and 31.3% vs. 16%, respectively). Al-
though statistical significance was only reached for males, the trial 
described the same results for those discharged alive. For patients 
discharged alive, there was no difference between those in the 
streptokinase arm and the control arm females had worse out-
comes. (female mortality rate 11.6% streptokinase) vs. 11.5% con-
trol, male mortality rate 6.3% for both the streptokinase and the 
control arms) [11].  
 In the Danish Trial in Acute Myocardial Infarction-2 
(DANAMI2) trial, patients with ST elevation myocardial infarction 
(STEMI) were randomised to either percutaneous coronary inter-
vention (PCI) or thrombolysis. The trial examined patients who 
presented to hospitals without the availability of PCI on site as well 
as those who presented to PCI-capable hospitals. The primary end 
point was 30-day mortality, clinical evidence of re-infarction or 
disabling stroke. The proportion of females was 27%, with no dif-
ference in the proportion of females between the two arms. The 
investigators demonstrated no difference in rates of mortality or 
stroke by intervention or control. There was, however, a reduction 
the in the rate of reinfarction (1.6% in the PCI group compared with 
6.3% in the thrombolysis group; P<0.001). Moreover, females who 
received PCI had better outcomes compared with females who re-
ceived thrombolysis and, notably, received a greater benefit than 
males (odds ratio (OR) for female 0.47 (95%CI 0.27-0.81 P=0.005) 
vs. male 0.59 (95% CI 0.39-0.90, P=0.01) [12].  
 The Clopidogrel as Adjunctive Reperfusion Therapy (CLAR-
ITY) trial considered the addition of clopidogrel to aspirin and fi-
brinolytic therapy for patients with STEMI. The primary outcome 
was a composite of an occluded infarct-related artery at angiogra-
phy, death or recurrent myocardial infarction prior to angiography. 
The proportion of females in the trial was 20%. The investigators 
found that the addition of clopidogrel resulted in an absolute risk 
reduction of 6.7% for the primary endpoint. Additionally, there was 
a higher incidence of the primary endpoint among females who 
received clopidogrel or placebo compared with males (16.9% vs. 
14.5% and 24.7% vs. 20.8%, respectively) [13].  
Reperfusion Therapy for AMI  Observational Registries  
 The SHOCK registry comprised patients who were not random-
ised to a treatment arm of the SHOCK trial. There were more fe-
 
Fig. (1). Flow chart of article selection. 
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males in the registry than in the trial (36% vs. 32%, respectively). A 
higher proportion of females underwent PCI than medical therapy 
(37% vs 27%). There was a survival benefit for males who received 
revascularisation, though this benefit was not apparent among fe-
males [14].  
 Boucher et al. used the Quebec hospital registry to look at use 
of thrombolysis and outcomes with respect to age. Here the propor-
tion of females was 30%, who were older than males. Being female 
carried an adjusted OR of 1.36 (95% CI 1.04 -1.79) for in hospital 
mortality [15].  
 In the Acute Myocardial Infarction in Switzerland (AMIS) Plus 
registry the proportion of females was 28%. Females more fre-
quently than males had cardiogenic shock (10% vs. 8%). However, 
females tended to develop cardiogenic shock during their admission 
rather than present with it (77% vs. 23%). Being female was a pre-
dictor for both in-hospital mortality and the development of cardio-
genic shock, although neither were statistically significant. When 
the temporal trends were examined then the incidence of cardio-
genic shock is decreasing. This is being driven by a reduction in the 
development of cardiogenic shock during admission [16].  
 The Myocardial Ischaemia National Audit Project (MINAP) 
was studied to look at age dependent in-hospital mortality. The 
prevalence of females within the study population was 35%. They 
modelled their groups by sex, as there was significant interaction 
between age, in-hospital mortality and sex for both STEMI and 
NSTEMI (P<0.001). As age increased so did the OR for all cause 
in-hospital mortality. Being male conferred a higher adjusted OR in 
all age groups for both STEMI and NSTEMI [17].  
 The Vienna STEMI Registry examined the impact of updated 
guidelines on clinical outcomes; in their cohort 28% of patients 
were female. In-hospital mortality rates for females were double 
that of males (14.7% vs. 7.4%, P<0.001). The worst outcomes were 
seen in females who did not undergo reperfusion; who had in-
hospital mortality rates of 21.2%. Even so, sex was not found to be 
an independent predictor of death [18].  
 The Swedish RIKS-HIA registry was used to report long-term 
outcomes for patients with STEMI who underwent reperfusion. The 
proportion of females was 30%, with a higher frequency of females 
in the hospital thrombolysis group compared to pre-hospital throm-
bolysis and primary PCI (PPCI). Although the authors did not 
comment on sex-specific outcomes, it did not appear a significant 
factor in the regression models [19]. 
 Valente et al. investigated gender differences in patients with 
STEMI treated with PCI. Females comprised 26% of the cohort. 
There was no significant difference in the angiographic characteris-
tics of patients. Females were more likely to die in hospital and also 
more likely have major bleeding, but neither was significant when 
multilevel regression analysis was performed  [20].  
Medications - RCTs 
 The Clopidogrel in Unstable angina to prevent Recurrent 
Events (CURE) trial tested the efficacy of clopidogrel in addition to 
aspirin in ACS patients without electrocardiographic ST-segment 
elevation. The primary outcome was death from cardiovascular 
cause, non-fatal myocardial infarction or non-fatal stroke. The pro-
portion of females in the trial was 39%. Those who received clopi-
dogrel in addition to aspirin had a lower rate of the primary end-
point than those who received aspirin alone (relative risk 0.8, 
P<0.001). The effect was not reported to be as pronounced in fe-
males compared with males, although the exact figures were not 
provided [21].  
 The TRial to assess Improvement in Therapeutic Outcomes by 
optimizing platelet InhibitioN with prasugrel (TRITON) trial com-
pared prasugrel with clopidogrel among patients with ACS sched-
uled for PCI. The primary endpoint was death from cardiovascular 
cause, non-fatal myocardial infarction and non-fatal stroke at 
15months. The prevalence of females was 25%. The trial showed a 
reduction in the primary endpoint associated with prasugrel (Hazard 
Ratio (HR) 0.81, P<0.001). This effect was largely driven by a de-
crease in the rate of non-fatal myocardial infarction. For females the 
benefit of prasugrel was not as marked as that in males, with a 12% 
risk reduction for females as opposed to 21% for males [22].  
 The PLATelet inhibition and patient Outcomes (PLATO) trial 
assessed the use of ticagrelor compared with Clopidogrel in patients 
with ACS. The prevalence of females was 28% and did not differ 
between the groups. There were similar significant reductions in the 
primary endpoint of 12 month rates of death from vascular cause, 
MI or stroke for females and males (HR 0.83 vs. 0.85, respectively) 
[23].  
 The PEGASUS trial investigated the impact of the longer-term 
use of ticagrelor, starting at 12 to 36 months post AMI. The propor-
tion of female patients was 24% across the three groups of ticagre-
lor 90 mg bid, ticagrelor 60 mg bid and placebo. They showed a 
statistically significant reduction in the event rate for both ticagrelor 
groups compared to placebo, but no difference between the two 
ticagrelor groups. There was no difference when they examined the 
outcomes with respect to sex, however, better outcomes were evi-
dent in females compared with maleswho received the 90 mg tica-
grelor dose (HR 0.74 vs. 0.98) [24].  
 The ATLAS ACS2-TIMI 51 trial added rivaroxaban to standard 
ACS (acute coronary syndrome) treatment and compared its effects 
on death from cardiovascular cause, myocardial infarction or 
stroke. In their subgroups the prevalence of females was 25.1%, 
25.6% and 25%. They demonstrated a significant reduction in their 
primary end point for rivaroxaban and interestingly showed a 
greater benefit for females than males (HR 0.77 (95% CI 0.60-0.99) 
vs. 0.87 (95% CI 0.75-1.01) P=0.40). There was a higher bleeding 
rate in females in comparison to males (HR 6.41 (95% CI 1.52-
27.09) vs. 3.66 (95% CI 2.21-6.09) P=0.47) [25]. 
 GISSI3 considered the use of lisinopril and transdermal GTN in 
patients with AMI. The primary outcome was death at 6-weeks; 
22% of the participants were female. The trial showed an improve-
ment for all the interventions, although GTN on its own was not 
significant. For females, compared with males, there was a reduc-
tion in the primary endpoint of 11% for lisinopril (20.8% vs. 23.4% 
2P=0.039), 10% with GTN (20.9% vs. 23.3% 2P=0.048) and 21% 
reduction when used in combination (19% vs 24%.2P=0.005) [26].  
 The Survival and Ventricular Enlargement (SAVE) trial as-
sessed the impact of captopril versus placebo on mortality from all 
causes. The proportion of females was 18%. It demonstrated a 21% 
risk reduction for captopril (P=0.014). The benefit for females was 
much less than males (risk reduction for death from all causes for 
females 2% (95% CI -53 to 37) vs. males 22% (95% CI 2 to 36); 
cardiovascular death and morbidity females 4% (95% CI -32 to 30) 
vs. males 28%(95% CI 16 to 38)) [27]. 
 The Valsartan in acute myocardial infarction (VALIANT) trial 
investigated the use of valsartan or valsartan plus captopril against 
captopril for patients with AMI and either heart failure or left ven-
tricular dysfunction. The proportion of females was 31%. There 
was no statistical benefit seen and indeed the trial was discontinued 
due to adverse effects. However, it demonstrated a non-significant 
trend among females for a reduction in death from any cause and 
combined cardiovascular end point with valsartan versus captopril 
[28].  
 The Metoprolol in Acute Myocardial Infarction (MIAMI) trial 
studied the efficacy of metoprolol versus placebo on death at 15-
days. The proportion of females was 22%. It demonstrated a non-
significant improvement in survival with metoprolol. This differ-
ence persisted and was similar for females and males (4.4% vs. 
4.2%), however, females in the placebo arm had worse outcomes 
than males (6.2% vs. 4.5%) [29].  
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Table 1. Included studies. 
Authors Year Type ACS group 
Number 
patients 
Prevalence 
Females 
Primary Outcome 
Reperfusion Therapy for AMI  RCTS 
GUSTO investgators [7] 1997 RCT STEMI 1641 25% 
Death, non-fatal disabling stroke or non-fatal 
reinfarction at 30 days 
ISIS 2 investigators [8] 1988 RCT AMI 17187 23% Mortality at 35 days 
ISIS investigators [9] 1986 RCT AMI 16027 23% 7 day mortality 
Hochman et al. [10] 2006 RCT STEMI 302 32% Mortality 
GISSI Authors [11] 1987 RCT AMI 11696 20% Mortality at 12 months 
Anderson et al. [12] 2003 RCT STEMI 1572 27% 
Death, non-fatal disabling stroke or non-fatal 
reinfarction at 30 days 
Sabatine et al. [13] 2005 RCT STEMI 3491 20% 
Occluded infarct related artery on angiography, 
death or recurrent myocardial infarction prior to 
angiography 
Reperfusion Therapy for AMI  Observational Registries 
Hochman et al. [14] 1999 Registry STEMI 302 32% Mortality at 30 days 
Boucher et al. [15] 2001 Registry AMI 3741 30% Use of thrombolysis and outcomes 
Jeger et al. [16] 2008 Registry ACS 23696 28% Treatment and outcomes 
Gale et al. [17] 2011 Registry ACS 2229546 35% In-hospital mortality 
Kalla et al. [18] 2006 Registry STEMI 1053 28% Outcomes 
Stenestrand et al. [19] 2006 Registry STEMI 26205 30% Long term outcomes 
Valente et al. [20] 2010 Registry STEMI 1127 26% Gender differences in STEMI patients 
Medications  RCT 
Yusef et al. [21] 2001 RCT UA/NSTEMI 12562 38% CV mortality, non-fatal MI, or non-fatal stroke 
Wiviott et al. [22] 2007 RCT ACS 13608 25% CV mortality, non-fatal MI, or non-fatal stroke 
Wallentin et al. [23] 2009 RCT ACS 18624 28% CV mortality, non-fatal MI, or non-fatal stroke 
Bonaca et al. [24] 2015 RCT 
12-36 months post 
MI 
21162 24% CV mortality, non-fatal MI, or non-fatal stroke 
Mega et al. [25] 2012 RCT ACS 15342 25% CV mortality, MI, or stroke 
Devita et al. [26] 1994 RCT AMI 19394 22% 6 week mortality 
Pfeffer et al. [27] 1992 RCT 
MI and either 
impaired LV or 
HF 
2231 18% All cause mortality 
Pfeffer et al. [28] 2003 RCT 
MI and either 
LVSD or HF 
14703 31% All cause mortality 
Herlitz et al. [29] 1985 RCT AMI 5778 22% Mortality at 15 days 
Chen et al. [30] 2005 RCT AMI 45852 28% Death, reinfarction, cardiac arrest at 28days 
Pitt et al. [31] 2003 RCT 
MI and either 
LVSD or HF 
6642 29% 
Time to death from any cause, time to death 
from CV cause and hospitalisation for CV event 
Schwartz et al. [32] 2001 RCT UA/NSTEMI 3086 36% 
All cause mortality, nonfatal MI, cardiac arrest 
with resuscitation, rehospitalisation for ACS 
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Authors Year Type ACS group 
Number 
patients 
Prevalence 
Females 
Primary Outcome 
Cannon et al. [33] 2004 RCT ACS 4162 22% 
Death, MI, UA requiring hospitalization, revas-
cularization at  30 days, or stroke 
Cannon et al. [34] 2015 RCT ACS 18144 24% 
CV mortality, major CV event, or non-fatal 
stroke 
Medications  Observational Registries 
Dziewierz et al. [35] 2007 Registry NSTEACS 807 46% Use of medication and outcomes 
Invasive Strategy  RCT 
Fox et al. [36] 2010 MA NSTEACS 5467 32% 5 year mortality 
Ragmin et al. [37] 1999 RCT NSTEACS 2457 30% Death or MI at 6 months 
Lagerqvist et al. [38] 2006 RCT NSTEACS 2457 30% 5 year mortality 
de Winter et al. [39] 2005 RCT NSTEACS 1200 27% 
Death, MI or rehospitalisation for angina within 
12months of randomisation 
Fox et al. [40] 2002 RCT NSTEACS 1810 38% 
Death or non fatal MI at 12months, and Death, 
non fatal MI or refractory Angina at 4 months 
Fox et al. [41] 2005 RCT NSTEACS 1810 38% 5 year mortality 
Henderson et al. [42] 2015 RCT NSTEACS 1810 38% 10 year mortality 
Invasive Strategy  Observational Registries 
Anderson et al. [43] 2012 Registry Post PCI 426996 42% Outcomes 
Roe et al. [44] 2009 Registry NSTEACS 19336 42% Long term outcomes 
Ryan et al. [45] 2005 Registry NSTEACS 56352 39% Timing of intervention 
Mortality and Outcomes  Observational Registries 
Collart et al. [46] 2012 Registry AMI 2936 25% Patient characteristics 
Taneja et al. [47] 2004 Registry NSTEACS 653 39% 4 year outcomes 
Gulliksson et al. [48] 2009 Registry AMI 589341 36% Risk recurrent MI 
Gurjeva et al. [49] 2005 Registry NSTEACS 2948 46% Characteristics and outcomes 
Hansen et al. [50] 2012 Registry AMI 1595 52% 
All cause mortality, recurrent MI, discharge 
medication prescription 
Jneid et al. [51] 2008 Registry AMI 78254 39% Outcomes and medical care 
Langorgen et al. [52] 2009 Registry First AMI 11878 36% Short and long term outcomes 
Lopez de Sa et al. [53] 2002 Registry NSTEACS 4115 33% Outcomes at 90 days 
Montaye et al. [54] 2013 Registry ACS 1960 24% Mortality and patient characteristics 
Shah et al. [55] 2012 Registry AMI 187803 33% Risk HF 
Steg et al. [56] 2004 Registry ACS 16166 35% Risk HF 
Kyto et al. [57] 2015 Registry NSTEMI 48584 45% Incidence NSTEMI 
Bahler et al. [58] 2011 Registry AMI 15711 27% Age at first mi 
Radomska et al. [59] 2013 Registry STEMI 26035 35% 
Outcomes and treatments with special considera-
tion for diabetes 
Rasmussen et al. [60] 2005 Registry First AMI 64321 38% Outcome 28 and 365 days 
Abbreviations: 
RCT; Randomised Control Trial, ACS; Acute Coronary Syndrome, UA; Unstable Angina, CV; cardiovascular, HF; Heart Failure, STEMI; ST elevation myocardial infarction, MI; 
Myocardial Infarction, NSTEMI; non ST elevation myocardial infaction, NSTEACS; non ST elevation acute coronary syndrome, AMI; acute myocardial infarction, LVSD; left 
ventricular systolic dysfunction. 
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 The Clopidogrel and Metoprolol in Myocardial Infarction 
(COMMIT) trial investigated metoprolol versus placebo in patients 
with AMI. The primary outcome was a composite of death, re-
infarction or cardiac arrest at 28 days. The proportion of females in 
the study was 28%. The trial found no improvement in the primary 
outcome from the use of early metoprolol, although it was felt this 
might be due to higher rates of cardiogenic shock in the metoprolol 
arm. Interestingly, both the incidence of death and cardiogenic 
shock were increased in females compared with males (death fe-
males 11.8% vs. males 6.3%;cardiogenic shock females 6% vs. 
males 4.8%) [30].  
 The Eplerenone post-acute myocardial infarction heart failure 
efficacy and survival (EPHESUS) trial assessed the use of epler-
enone in patients with left ventricular dysfunction after AMI. The 
proportion of females was 28% in the intervention arm and 30% in 
the placebo arm. It found a statistically significant reduction in 
deaths from any cause and cardiovascular mortality or hospitalisa-
tion. There was a non-significant trend to reduced death from any 
cause for females, however, males on eplerenone were less likely to 
die from a cardiovascular cause or be hospitalized [31].  
 The Myocardial Ischaemia Reduction with Aggressive Choles-
terol Lowering (MIRACL) trial investigated whether atorvastatin 
reduced early cardiovascular events among patients with unstable 
angina and non ST-elevation myocardial infarction (NSTEMI). The 
proportion of females was 36%. It demonstrated a reduction in mor-
tality associated with atorvastatin. There was no significant interac-
tion between treatment assignment and sex [32].  
 The Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy (PROVE-IT) trial compared outcomes for ACS patients treated 
with either high intensity statins (i.e. atorvastatin 80mg) or moder-
ate dose statin (i.e. pravastatin 40mg). The primary outcome was 
death from any cause, myocardial infarction, unstable angina re-
quiring rehospitalisation, revascularisation within 30 days and 
stroke. The mean follow up was 24 months. The proportion of fe-
males was 22%. It showed that those on high intensity statins had 
better outcomes than those on a moderate dose statins (16% reduc-
tion in the HR P=0.005). The trial found that females on high inten-
sity statins had a greater benefit than males.  
 The two year event rate for females on high intensity statins 
was 20.3% and for males 23% [33].  
 The IMProved Reduction of Outcomes: Vytorin Efficacy Inter-
national Trial (IMPROVE-IT) trial considered the addition of 
ezetimibe to simvastatin versus simvastatin alone. The primary 
endpoint was cardiovascular death, major cardiovascular event 
(non-fatal AMI, hospitalisation for unstable angina, revascularisa-
tion within 30 days). It demonstrated a significant improvement for 
the group who received ezetimibe plus simvastatin (HR 0.936, 
P=0.016). There was a non-significant trend towards a greater 
benefit for females than males (HR 0.885 (95% CI 0.791 to 0.991) 
vs. 0.952 (95% CI 0.895 to 1.012) [34].  
Medications - Observational Registries 
 The Malopolska registry was interrogated to look at the treat-
ment of non ST-elevation ACS (NSTEACS). The proportion of 
females was 46%. The investigators assigned points for the use of 
guideline recommended therapies. Mortality decreased as the use of 
guideline directed therapy in hospital increased. In individual 
analysis, statin use had the greatest effect (OR 0.11, 95% CI 0.058-
0.208, P<0.0001). The prescription of aspirin,   blocker and 
ACEi/ARB all significantly reduced in-hospital mortality. The 
authors did not consider the prescription of medications by sex. In 
this study male sex was a predictor of raised in-hospital mortality, 
male sex conferred an OR of 1.46 (95% CI 0.74-2.90 P=0.280) 
[35].  
 
 
Invasive Strategy -RCTs 
 There have been three randomised control trials of invasive 
strategies for patients with ACS that have presented five year out-
come data. Fox et al. published the FRISC2, ICTUS and RITA3 
trials long-term outcomes as a meta-analysis. This showed a reduc-
tion in the composite endpoint of death and myocardial infarction 
for those who routinely underwent an invasive strategy compared 
with those who received a selective invasive strategy (HR 0.81 
P=0.002). Females had slightly better outcomes than males (mortal-
ity 15% vs. 16.2%, respectively; OR 1.1, P=0.2) [36].  
 The Fast Revascularization During Instability in Coronary Ar-
tery Disease (FRISC)-II trial investigated patients with NSTEACS 
 assigning them to either an invasive or non-invasive strategy. The 
primary endpoint was death or AMI at 6 months. The investigators 
demonstrated a reduction in the primary endpoint among those who 
received a routine invasive strategy. In the subgroup analysis for the 
primary endpoint, however, females did better with a non-invasive 
strategy (8.3% vs. 10.5%, risk ratio 1.26). Males had better out-
comes when an invasive strategy was employed. When the investi-
gators considered the effect on angina symptoms at 6 months, an 
invasive strategy was found to be superior among females (risk 
ratio 0.64) [37]. The five-year outcomes for FRISC-II showed a 
significant improvement in the primary endpoint for all groups, 
mostly driven by a reduction in rates of AMI. Females continued to 
have better outcomes when a non-invasive strategy was employed 
(relative risk for an invasive strategy 1.12, 95% CI0.83-1.5, 
P=0.01) [38].  
 The Invasive versus Conservative Treatment in Unstable Coro-
nary Syndromes (ICTUS) trial assessed the merits of an invasive 
strategy in patients with NSTEACS; the primary endpoint was a 
composite of death, AMI or rehospitalisation for angina within 12 
months of randomisation. The proportion of females was 27%. 
There was no benefit associated with an early invasive strategy over 
optimal medical therapy plus selective invasive strategy. In the 
subgroup analysis, there was a trend for females to favour an early 
invasive strategy when compared to males, although females had 
worse outcomes than males regardless of the strategy that was used 
(primary end point 25.7% vs. 20.3%) [39].  
 The Randomised Treatment of Angina (RITA 3) trial random-
ised patients to early intervention versus conservative management. 
The study had co-primary endpoints of death or non-fatal AMI at 
12 months and death, non-fatal AMI and refractory angina at 4 
months. The proportion of females was 38%, with a slightly higher 
proportion in the intervention group 39% vs. 36%. There was a 
reduction in the primary end point at both 4 months (risk ratio 0.66 
95 % CI 0.51-0.85 P=0.001) and 12 months (risk ratio 0.72, 95% CI 
0.58-.090, P=0.003) and driven by a reduction in rates of refractory 
angina. At 12 months females in the conservative group had a lower 
incidence of death or AMI (5.1% vs. 8.6%). Males in whom an 
invasive strategy was employed had better outcomes at both 4 and 
12 months. (40) The five-year outcomes show the benefit accrued 
by an early invasive strategy over a conservative one. Being male 
carried a greater risk of primary outcome (OR 1.44 95% CI 1.09-
1.89, P=0.0099). (41) The recently published 10 year outcomes for 
RITA 3 demonstrated no difference in mortality between the 
groups. Male, however, continued to carry an increased risk of 
death (OR 1.3, 95% CI 1.00-1.68, P=0.051) [42].  
Invasive Strategy - Observational Registries 
 Anderson et al. investigated the short and long term outcomes 
of coronary stenting with respect to sex using the NCDR Cath PCI 
registry. The proportion of females was 42%. All patients were 
aged >65 with females being, on average, older than males (mean 
age 76 vs. 74 years). Females had a higher unadjusted risk of death 
(HR 1.06, 95% CI 1.04-1.07) and lower adjusted risk of death at 30  
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months (HR 0.92, 95% CI 0.9-0.94, P=0.002). They did however, 
have a higher risk of in-hospital death. For both males and females 
drug-eluting stents) were associated with better outcomes than bare 
metal stents [43].  
 Roe et al. used the CRUSADE registry to assess long-term 
outcomes in older patients with NSTEMI. The proportion of fe-
males was 42%. Patients were split according to treatment strategy; 
medical management, PCI and CABG. Females were less likely to 
be in the CABG group than any other (P<0.0001). The group who 
received CABG had the best outcomes at five years; those who 
underwent medical management had the worst outcomes [44].  
 The Can Rapid risk Stratification of Unstable angina patients 
Suppress Adverse outcomes with Early implementation of the 
ACC/AHA guidelines (CRUSADE) registry investigate the optimal 
timing of intervention in patients with NSTEACS. The investigators 
divided patients into groups based on the day of admission to hospi-
tal. The proportion of females was 39% which did not differ be-
tween weekday or weekend hospitalisation. There was an increase 
in the time to catheterisation for those admitted at the weekend 
compared with a weekday (46.3 hrs vs. 23.4 hrs). There was no 
significant difference in mortality rates for females between those 
admitted on a weekend (4.7%) and those on a weekday (4.7%). The 
authors found a difference between those admitted on a weekend 
and weekday for males (4.2% vs. 3.7%). Females had a higher mor-
tality rate than males [45].  
Mortality and Outcomes Registries  
 The Charleroi registry in Belgium examined 25-69 year olds 
with AMI between 1998 and 2007 in biennial periods. The propor-
tion of females was 25% and did not change over the study period. 
Females were older (58 vs. 55 years) and more frequently had dia-
betes and hypertension, and less frequently smoked or had previous 
AMI (P<0.001 for all values). There was an increase in the utilisa-
tion of therapies over time; males were more likely to have reperfu-
sion therapy than females (Odds ratio for thrombolysis 1.65 
P<0.001; PTCA OR 1.32 P=0.022). Receiving thrombolysis re-
sulted in a reduction in mortality for males (OR 0.39 P<0.001), this 
however, was not seen in females in whom receiving thrombolysis 
resulted in no improvement in mortality (OR 1.07 P=0.846). There 
was no statistically significant difference in the use of antiplatelets 
or   blockers by sex, though ACE inhibitors were more frequently 
prescribed for males. The authors did look at 28 day mortality and 
reported no significant difference with regard to sex, they did note 
being male carried a slightly higher risk than being female (OR 
1.15 P=0.648) [46].  
 The Prospective Registry of Acute Ischaemic Syndromes 
(PRAIS) UK registry assessed long-term outcomes following 
NSTEMI. It reported a higher rate of death among males (HR 1.78, 
95% CI 1.22  2.59, P=0.003) [47].  
 Gulliksson et al. analysed 775,901 events in patients aged be-
tween 20 and 84 years from 1972 to 2001 to look at the risk of re-
current AMI. The proportion of females was 36%, who were more 
likely than males to die within 28 days after both the index AMI 
(23.8% vs. 19.3% P<0.0001) and recurrent AMI (23.2% vs. 21.3% 
P<0.0001). There was a reduction in the mortality rate for both 
males and females from 1972 to 2001. Females were also more 
likely to have recurrent AMI than males (average recurrent AMI 
per patient 1.48 for females vs. 1.42 for males) [48].  
 Gurjeva et al. used the Global Unstable Angina Registry and 
Treatment Evaluation (GUARANTEE) registry to look at the im-
pact of both gender and age on patients with NSTEACS. The pro-
portion of females in the cohort was 46% although females tended 
to be older; 55% were >75 as opposed to 36% <75 (P<0.001). Al-
though older females were more likely to be diagnosed with AMI 
on admission, they were less likely to be cared for by a cardiologist. 
PCI was performed more frequently in males than females and also 
younger females as opposed to older females (13.7% vs. 8.1%). In 
addition to not receiving PCI, females were less likely to be dis-
charged on aspirin or   blockers compared to males despite having 
similar rates of use to males prior to admission. Overall the use of 
medications was low for all groups. The study demonstrated that 
with respect to in hospital outcomes; the group that had the worst 
outcomes (death or MI) were elderly females [49].  
 Hansen et al. used the Danish registries from 2005-07 to iden-
tify patients with AMI and assess their prognosis and treatment in 
those without significant coronary stenoses. The proportion of fe-
males was 52%. Females were more likely to die within three years 
than males (HR 1.22, 95% CI 0.86-1.72) although less likely to 
have a recurrent event (HR 0.84, 95% CI 0.50-1.43) [50].  
 Jneid et al. studied medical care and early death following AMI 
with respect to sex using the Get With the Guidelines  Coronary 
Artery Disease database. The proportion of females was 39%. Fe-
males were older than males (mean age 73 vs. 65). Females with 
STEMI were less likely to receive acute reperfusion (56.3% vs. 
73% P<0.0001). This discrepancy was also seen in other invasive 
procedures  angiography (45.6% vs. 56.2% P<0.0001) PCI (36.1% 
vs. 52.3% P<0.0001) CABG (5.4% vs. 9.2% P<0.0001). These 
differences persisted after multivariable adjustment. The unadjusted 
mortality rate was higher for females than males (8.2% vs. 5.7%, 
P<0.0001) and also for those with STEMI (10.2% vs. 5.5% 
P<0.0001), but after multivariable adjustment was only significant 
for STEMI (OR 1.12, 95% CI 1.02  1.23, P=0.015) [51].  
 The Western Norway cardiovascular registry studied short- and 
long-term mortality in patients who were hospitalised with first 
AMI from 1979  2001. The proportion of females was 36%. The 
investigators considered mortality at 28 days, one year and 10 years 
across three time periods, 1979-1985, 1986-1993 and 1994-2001. 
They demonstrated consistent higher crude mortality rates for fe-
males when compared to males. For both males and females the 
mortality rate declined as time advanced. There was no significant 
age and sex-adjusted differences in mortality for those under 60 
years, but for those over 60 years mortality rate were significantly 
lower at each time point [52].  
 The Proyecto de Estudio del Pronostico de la Angina (PEPA) 
registry focused on patients with NSTEACS, 90-day mortality and 
predictors of this. A third of the patients were female. The rates of 
cardiovascular mortality were 4.3% and cardiovascular death or 
AMI 6.9%. Whilst females were more likely to die than males 
(5.2% vs. 3.3%, P=0.005), sex was not an independent predictor 
[53].  
 Montaye et al. considered the differences between regions in 
France in patients who were part of the MONItoring of Trends and 
Determinants in CArdiovascular Disease (MONICA) registry. Fe-
males comprised 24% of the entire cohort, who had similar mortal-
ity rates at both 28 days and one year to males [54].  
 Shah et al. used the CRUSADE registry to investigate the risk 
of heart failure complicating acute MI. The proportion of females 
was 33%, who more frequently had NSTEMI than STEMI (65% vs. 
35%). Females were more likely than males to develop heart failure 
during their index admission (OR 1.25, 95% CI 1.18  1.32, 
P<0.0001) and this remained evident after patients with a history of 
prior heart failure were excluded (OR 1.26, 95% CI 1.19  1.33, 
P<0.0001) [55].  
 Steg et al. used the Global Registry of Acute Coronary Events 
(GRACE) registry to study the impact of heart failure on admission 
among patients with ACS. Females were more likely to present 
with heart failure than males (OR 0.8, 95% CI 0.72-0.93). Those 
who presented with heart failure were less likely to undergo inva-
sive treatment and had worse outcomes than those who didnt [56].  
 Kyto et al. used the Finnish Hospital Discharge Registry to 
calculate the incidence of NSTEMI from 2001 to 2008. Overall 
males more frequently had an AMI than females (relative risk 1.86, 
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95% CI 1.60  2.16, P<0.0001). However, as age increased so did 
the frequency of AMI in females. In fact the group most likely to 
have an AMI were females aged between 80 and 85 years [57].  
 Bahler et al. used the AMIS Plus registry to look at the age of 
first AMI among smokers; 27% of the patients were females. 
Smokers had their first AMI at a younger age than their non-
smoking counterparts and this was more pronounced in female 
smokers (13.1 years for female vs. 10.2 for males). When other 
factors had been adjusted for, female smokers continued to demon-
strate this trend. The sex specific difference was 2.1years (P<0.001) 
[58].  
 Radomska et al. used the Polish Registry of Acute Coronary 
Syndromes (PL-ACS) registry to look the effect of type 2 diabetes 
among females with STEMI. The proportion of females was 34% 
and females more frequently had diabetes. Females with diabetes 
compared with males with diabetes had worse outcomes, which 
commenced in-hospital (In-hospital mortality 15.5% vs. 10.3%, 
P<0.0001) and extended to 12 months (28.5% vs. 21.1%, 
P<0.0001). Females received an invasive treatment less frequently 
and were less likely to receive guideline-indicated therapies. Com-
pared with females without diabetes, similar findings were demon-
strated (In-hospital mortality 15.5% vs. 10.6%, P<0.0001 and 12 
month mortality 28.5% vs. 19.4%, P<0.0001) [59].  
 Rasmusson et al. used the Danish National Hospital Registry to 
assess outcomes for patients with a first presentation of AMI. The 
proportion of females was 38%. There was no difference between 
females and males with regards to mortality at one year. However, 
at 28 days there was an increase in mortality for females (OR 1.09, 
95% CI 1.04  1.14, P<0.001) [60].  
DISCUSSION 
 This structured review of 56 papers comprising 2,538,327 pa-
tients has found that among RCTs and observational registries alike 
that females are underrepresented in studies, have high mortality 
rates following AMI and are less likely to receive guideline-
indicated care.  
 There have been several trials [7-9, 11-13, 61-63] concerning 
reperfusion and ACS. Five RCTs demonstrated that females did 
worse than males [7-9, 11,13]. Four manuscripts demonstrated this 
was across all groups including interestingly the placebo group [8,9, 
11, 13]. One trial showed no difference in mortality at 30 days [12].  
 There have been four registries considering reperfusion and 
ACS [14, 16, 19, 20]. All three demonstrated worse outcomes for 
females in comparison to males.  
 The data from both registries and RCTs, which allow outcomes 
to be considered with respect to sex for patients receiving reperfu-
sion, suggest that overall females have worse outcomes than males. 
This may relate to a reduction in the use of guideline driven therapy 
in females when compared to males [18, 64]. It may relate to the 
fact that women take longer to present to hospital than men and that 
in addition there is a delay in the time to make decisions for females 
in comparison to males [65]. In comparison when the National Reg-
istry of Myocardial Infarction data from 1994 to 1998 was interro-
gated to assess the role of the ambulance as method of transporta-
tion to hospital. Using the ambulance resulted in faster reperfusion 
times females were more likely to use the ambulance service than 
males. However the results interestingly also revealed worse out-
comes in those transported by ambulance despite the fact they re-
ceived reperfusion faster [66]. The outcomes may be worse in part 
due to the higher incidence of cardiogenic shock in females [16].  
 Four RCTs have looked at antiplatelet use. Two showed a supe-
rior benefit for males [21, 22] two showed a superior benefit in 
females [23, 24] though this was for the same drug. 
 Two RCTs looked at ACE/ARB use [27, 28]. Males did better 
with prescription of ACEi [27, 28] whilst there was a trend for fe-
males to have better outcomes than those on ACEi and also males 
receiving ARBs [28]. Both studies showed better outcomes for 
those who received the medication. 
 Two studies considered beta-blocker use and both focussed on 
metoprolol [29, 30]. Both studies showed females had better out-
comes when on treatment. Females in both placebo groups had 
worse outcomes than males, one repeated this finding across the 
study [30].  
 Three RCTs considered lipid-lowering medication. Two 
showed females had better outcomes with respect to males within 
the intervention arm [33, 34]. One registry focussed on lipid lower-
ing medication and showed females were less likely to receive lipid 
lowering therapy, also those who didnt receive lipid lowering ther-
apy were also less likely to be prescribed other guideline driven 
therapies [67].  
 Two registries considered medication prescribing as a whole 
and this prescribing in relation to guidelines [35, 68]. Those on 
guideline directed therapy had better outcomes, although only one 
considered sex as a factor for this prescription and demonstrated no 
difference. 
 When considering medication use receiving the medication of 
interest results in better outcomes. Patients within RCTs that fo-
cussed on a specific medication would receive that medication. This 
allows comparison between treatments. However, registries look at 
what patients actually use and so reflect the real world where guide-
line therapy may be contraindicated. Two registries demonstrated 
that females were less likely to get guideline directed therapy [64, 
69]. 
 There is no clear correlation between outcomes and medication 
use with respect to RCTs and registries, this in part is likely due to 
the fact that the outcomes they focus on differ. What is clear is that 
being on guideline directed therapy results in better outcomes. Fe-
males in particular should be targeted for high intensity statins. 
When considering antiplatelet therapy; ticagrelor is probably the 
best choice for females in comparision to clopidogrel and prasugrel 
as this was the only antiplatelet agent that demonstrated better out-
comes for females than males with in the RCTs.  
 One study considered anticoagulation for patients post ACS, 
females received more benefit than males did, although they did 
have a higher bleeding rate than men, so the net benefit of receiving 
the rivaroxaban remains unclear [25]. 
 Three RCTs considered outcomes in NSTEACS patients with 
regards the timing/use of an invasive strategy. Two demonstrated 
an invasive strategy resulted in better outcomes for males, both of 
these also showed a trend for females to have better outcomes for 
mortality with a conservative approach [37, 40]. One in contrast 
showed that females did better with an invasive approach, although 
females still had worse outcomes [39].  
 Three registries have focussed on invasive strategies. Two 
demonstrated worse outcomes for females [44, 45]. One demon-
strated worse short term outcomes, but better long term outcomes 
(30 months) for females [43].  
 The registries and RCTs agree that generally females have 
worse outcomes than males, what is interesting is the trend demon-
strated by two of the RCTS that females have better outcomes when 
managed conservatively for NSTEACS. If you consider a typical 
female NSTEACS patient they are often elderly and may well have 
co-morbidities that may prohibit an invasive approach. More work 
is needed here to determine the optimal strategy for this group of 
patients. 
 The registries that have focussed on reporting outcomes have 
demonstrated that males are more likely to receive an intervention 
(thrombolysis, medication, or angioplasty) than females [46, 70, 
71].  
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 Generally the trend demonstrated was that if you received the 
specified intervention that was the focus of the article then your 
outcomes improved. 
 Two registries considered people who had heart failure in the 
context of ACS. Females were more likely to both; present or de-
velop heart failure than males. Those with heart failure generally 
had less invasive treatment and had worse outcomes [55, 56]. 
 Two registries considered at risk groups- smokers and diabetes 
respectively. In both registries females with these risk factors had 
poorer outcomes. Those who smoked had their first MI at an earlier 
year than their male counterparts [58]. Whilst those with diabetes 
had worse outcomes most likely related to the underuse of guideline 
directed therapy and intervention [59]. Interestingly the registry 
concerned with diabetes also showed these trends in females with-
out diabetes. 
Strengths and Limitations 
 This has been a comprehensive systematic review of the avail-
able literature, however, given the broad nature of the topic there 
will inevitably be omissions of manuscripts. 
 The average proportion of females was 31.5% (18-38%). The 
proportion of females was higher in observational registries than 
RCTs, suggesting unequal sex representation between the two study 
designs. Which may influence outcomes.  
 For most registries specific gender data was not provided, they 
often reported with respect to age, the elderly (definition varied 
between papers) were less likely to receive the intervention of in-
terest. In all the registries included in this review females were 
older than males, so a higher proportion of females would have 
been in the elderly group that didnt receive the intervention. Where 
gender specific data was provided it had been adjusted for age, 
thereby eliminating the impact of the advanced age on mortality. 
CONCLUSION 
 Females are generally older and not receiving the same care as 
males, this may be appropriate as they are older and there may be 
contraindications to therapies. However, when considering RCTs 
females consistently seemed to have worse outcomes across both 
the placebo and intervention arms. 
 When considering longer-term outcomes one registry reviewed 
10-year outcomes and females had a higher crude mortality rate 
than males, and within the older age groups being female was asso-
ciated with higher risk of mortality [52].  
 An underlying theme was that females were less likely to re-
ceive guideline directed therapy and interventions than their male 
counterparts [49,51]. One can speculate it reflects the fact females 
often present in an atypical fashion, which may delay diagnosis. 
What is clear from the papers analysed if you did not receive the 
intervention or guideline directed care then your outcomes were 
worse. 
 There were some interesting trends from the RCTs which may 
merit further investigation, one was that females seemed to have 
better outcomes on ARBs as opposed to ACEi [28] and that females 
with NSTEACS appear to receive more benefit from a conservative 
approach than an invasive one with respect to outcomes [37, 40].  
 The main unanswered question is why females have worse out-
comes than males as this was seen across both the RCTs and the 
registries, be the females in the placebo or the intervention group. 
The reasons for this are not clear and would merit further investiga-
tion. 
 To improve the care for females the focus needs to shift to en-
suring that they receive guideline directed therapy when appropriate 
and an interventional strategy if this is deemed the correct strategy. 
 
Appendix 1. Search Strategy employed for literature search. 
1. Myocardial ischemia/ 
2. Acute coronary syndrome/ 
3. myocardial infarction/ 
4. (coronary adj2 syndrom*).tw. 
5. myocard* isch?emia*.tw. 
6. isch?emic heart disease*.tw. 
7. exp angina, unstable/ 
8. (unstable adj3 angina).tw. 
9. unstable coronary.tw. 
10. mi.tw. 
11. acs.tw. 
12. without st segment.tw. 
13. non-Q-wave.tw. 
14. NSTEMI.tw. 
15. STEMI.tw. 
16. or/1-15 [coronory syndrome] 
17. Patient Admission/ 
18. Hospitalization/ 
19. (readmission or readmitted or re-admission or re-admitted).tw. 
20. (rehospitali?ation* or re-hospitali?ation* or rehospitali?ed or re-
hospitali?ed).tw. 
21. (repeat* hospitali?ation* or repeat* hospitali?ed).tw. 
22. recurrent hospitali?ation*.tw. 
23. Hospitalization/ 
24. (hospitali?ation* or hospitali?ed).tw. 
25. (hospital adj1 admission*).tw. 
26. (admitted adj1 hospital).tw. 
27. Inpatients/ 
28. inpatient*.tw. 
29. Mortality/ 
30. Hospital Mortality/ 
31. Myocardial Revascularization/ 
32. exp stroke/ 
33. exp Heart Failure/ 
34. outcome*.tw. 
35. prognosis/ 
36. prospective studies/ 
37. treatment outcome/ 
38. or/17-37 [outcomes] 
39. 16 and 38 [coronary syndrome and outcomes] 
40. limit 39 to (english language and yr="2000 - 2015") 
41. limit 40 to (full text and human) 
42. limit 41 to ovid full text available 
43. registry/ 
44. registry.tw. 
45. 43 and 44 [registry] 
46. randomi?ed control trial.tw. 
47. randomized control trial/ 
48. RCT.tw. 
49. RCT/ 
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50. or/43-44 [registry] 
51. or/46-49 [RCT] 
52. 50 or 51 
53. 42 and 52 
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